CUPERTINO, Calif., April 17, 2017 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX), a biopharmaceutical company actively
developing new therapeutics based on its Epigenetic Regulator
Program and proprietary drug delivery platforms, announced today
that it will present clinical data on DUR-928 at the International
Liver Congress 2017 (the 52nd annual meeting of the
European Association for the Study of the Liver (EASL)), which will
be held April 19-23 in
Amsterdam.
The poster presentation will report safety, pharmacokinetics and
biomarker data from both cohorts of a Phase 1b study utilizing
DUR-928 in patients with nonalcoholic steatohepatitis (NASH).
Presentation
details:
|
Title:
|
"Safety and
pharmacokinetics of DUR-928 in patients
with
|
|
nonalcoholic
steatohepatitis – a phase 1b study"
|
Author:
|
W. Kemp et
al.
|
Poster:
|
#SAT-322
|
Day &
Time:
|
Saturday, April 22,
08:00-18:00 Central European Time
|
About the International Liver CongressTM
The International Liver Congress™ is the annual
meeting of European Association for the Study of the Liver, and the
flagship event in EASL's educational calendar. The Congress
is attended by scientific and medical experts from a broad range of
fields including hepatology, gastroenterology, internal medicine,
cell biology, transplant surgery, infectious diseases, microbiology
and virology, pharmacology, pathology, radiology and imaging.
Specialists share recent data, present studies and findings, and
discuss the hottest topics on liver disease. The 2017
Congress will take place April 19-23,
2017 at the RAI Amsterdam, Amsterdam, The Netherlands. The full EASL 2017
scientific program can be found at http://ilc-congress.eu/.
About DURECT
DURECT is a biopharmaceutical company actively developing new
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 1 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury, chronic metabolic diseases such as
nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH) and other liver diseases with both broad and
orphan populations, and inflammatory skin conditions such as
psoriasis. DURECT's advanced oral, injectable, and
transdermal delivery technologies are designed to enable new
indications and enhanced attributes for small-molecule and biologic
drugs. One late-stage product candidate in this category is
POSIMIR® (SABER®-Bupivacaine), an
investigational locally-acting, non-opioid analgesic intended to
provide up to 3 days of continuous pain relief after surgery.
Another late stage product candidate is REMOXY® ER
(oxycodone), an investigational pain control drug based on DURECT's
ORADUR® technology. For more information, please
visit www.durect.com.
NOTE: POSIMIR®, SABER®, and
ORADUR® are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners.
POSIMIR, DUR-928, and REMOXY ER are drug candidates under
development and have not been approved for commercialization by the
U.S. Food and Drug Administration or other health authorities.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential
benefits and uses of our drug candidates, including the potential
use of DUR-928 to treat NASH, other disorders of the liver,
acute organ injury, kidney diseases or psoriasis or other
inflammatory conditions, the potential use of POSIMIR and REMOXY ER
to treat pain, potential regulatory approvals of POSIMIR and REMOXY
ER, and potential markets for our product candidates are
forward-looking statements involving risks and uncertainties that
can cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the risks that future clinical
trials of DUR-928 do not demonstrate the safety or efficacy of
DUR-928 in a statistically significant manner, the potential that
FDA may not grant regulatory approval of DUR-928, POSIMIR or REMOXY
ER, the risks of obtaining marketplace acceptance of DUR-928,
POSIMIR or REMOXY ER, if approved, the risk of delays in the
commencement, enrollment or completion of clinical trials, the risk
that prior clinical trials (including prior Phase 1b trials of
DUR-928) will not be confirmed in subsequent trials, the potential
failure of clinical trials to meet their intended endpoints, the
risk of adverse decisions by regulatory agencies or delays and
additional costs due to requirements imposed by regulatory
agencies, additional time and resources that may be required for
development, testing and regulatory approval of DUR-928, potential
adverse effects arising from the testing or use of our drug
candidates, our potential failure to maintain our collaborative
agreements with third parties or consummate new collaborations and
risks related to our ability to obtain capital to fund operations
and expenses. Further information regarding these and other risks
is included in DURECT's Form 10-K filed on March 29, 2017 under the heading "Risk
Factors."
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/durect-to-present-clinical-data-at-the-international-liver-congress-2017-300439694.html
SOURCE DURECT Corporation